Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study

Maturitas

Volumn 28, Issue 2, 1997, Pages 147-151

  Grigoriou, Odisseas ^a   Papoulias, Ioannis ^a   Vitoratos, Nicolaos ^a   Papadias, Constantinos ^a   Konidaris, Sokratis ^a   Antoniou, George ^a   Chryssikopoulos, Athanasios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bone mineral density; Osteoporosis; Ovariectomized women; Salmon calcitonin

Indexed keywords

CALCITONIN; CALCIUM; CALCIUM GLUBIONATE; PLACEBO; SALCATONIN;

ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; OVARIECTOMY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INTRANASAL; ADULT; ANALGESICS; BONE DENSITY; CALCITONIN; CALCIUM; COHORT STUDIES; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYPROLINE; MIDDLE AGED; OSTEOCALCIN; OVARIECTOMY; POSTMENOPAUSE;

FALLOPIA;

EID: 0031573864     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(97)00071-6     Document Type: Article

References (25)

1. Riggs B.L., Melton III L.J. Involutional osteoporosis. N Engl J Med. 314:1986;1676-1686.
2. Gallagher J.C., Young M.M., Nordin B.E.C. Effect of artificial menopause on plasma and uring calcium and phosphate. Clin Endocrinol. 1:1972;57-64.
3. Mazzuoli G.F., Tabolli S., Bigi F., Minisola S., Scarda A., Scassellati G. Changes in bone remodelling and calcium-phosphorus metabolism following oophorectomy. Calcif Tissue Int. 39(Suppl):1986;56.
4. Stepan J.J., Prest J., Broulik P., Pacovsky V. Serum osteocalcin levels and bone alkaline phosphatase isoenzyme after oophorectomy and in primary hyperparathyroidism. J Clin Endocrinol Metab. 64:1987;1079-1082.
5. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomized women. Lancet 1980;ii:1151-1153.
6. Christiansen C., Lindsay R. Estrogens, bone loss and preservation. Osteoporosis Int. 1:1991;7-14.
7. Lindsay R. Estrogen therapy in the prevention and management of osteoporosis. Am J Obstet Gynecol. 156:1987;1347-1351.
8. Mazzuoli G.F., Passeri M., Gennari C., Minisola S., Antonelli R., Voltorta C., Palummeri E., Cervelli G.F., Gonnelli S., Francini G. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double blind clinical study. Calcif Tiss Int. 38:1986;3-8.
9. Renginster J.Y., Denis D., Albert A., Deroisy R., Lecart M.P., Fontaine M.A., Lambelin P., Franchimont P. 1-Year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet. 2:1987;1481-1483.
10. MacIntyre I., Whitehead M.I., Banks L.M., Stevenson J.C., Wimalawansa S.J., Healy M.J.R. Calcitonin for prevention of postmenopausal bone loss. Lancet. 1:1989;900-902.
11. Renginster J.Y. Calcitonin for prevention and treatment of osteoporosis. Am J Med. 95(Suppl 5A):1993;44S-47S.
12. Mazzuoli G., Tabolli S., Bigi F., Valtorta C., Minisola S., Diacinti D., Scarnecchia L., Bianchi G., Piolini M., Dell'Acqua S. Effects of salmon calcitonin on the bone loss induced by ovariectomy. Calcif Tiss Int. 47:1990;209-214.
13. Gruber H.E., Ivey J.L., Baylink D.J., Matthews M., Nelp W.P., Sisom K., Chesnut III C.H. Long term calcitonin therapy in postmenopausal osteoporosis. Metabolism. 4:1984;295-303.
14. Thamsborg G., Storm T., Sykulski R., Brinch E., Anderson N.F., Homegard S.N., Soerensen O.H. Intranasal calcitonin and prevention of postmenopausal bone loss. Lancet. 1:1988;413.
15. Overgaard K., Riis B.J., Christiansen C., Padenphaut J., Johansen J.S. Nasal calcitonin treatment of established osteoporosis. Clin Endocrinol (Oxf). 30:1989;435-442.
16. Overgaard K., Hansen M.A., Jensen S.B., Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis. A dose-response study. Br Med J. 305:1992;556-561.
17. Thamsborg G., Storm T.L., Sykulski R., Brinch E., Kaspersen Nielsen H., Helmer Soerensen O. Effect of different does of nasal salmon calcitonin on bone mass. Calcif Tiss Int. 48:1991;302-307.
18. Renginster J.Y., Denis D., Deroisy R., Lecart M.P., De Longueville M., Zegelis B., Sarlet N., Noirfalisse P., Franchimont P. Long term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Mineral Res. 9:1994;69-73.
19. Lyritis G.P., Magiasis B., Tsakalakos N. Prevention of bone loss in early nonsurgical and monosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment. Calcif Tiss Int. 56:1995;38-41.
20. Fioretti P., Gambacciani M., Taponeco F., Melis G.B., Capelli N., Spinetti A. Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women. Maturitas. 15:1992;225-232.
21. Polatti F., Perotti F., Angelini G.P., Vassellatti D., Rapisardi I. Effects of salmon calcitonin suppositories in the prevention of bone loss in oophorectomized women. Maturitas. 18(1):1993;73-76.
22. Krieger N.S., Feldman R.S., Tashjian A.H. Jr. Parathyroid hormone and calcitonin interactions in bone: irradiation-induced inhibition of escape in vitro. Calcif Tiss Int. 34:1982;197-203.
23. Nakamura T., Tovofuku F., Kanda S. Whole body irradiation inhibits the escape phenomenon of osteoclasts in bones of calcitonin-treated rats. Calcif Tiss Int. 37:1985;42-45.
24. Azria M. Calcitonin in therapeutic use. In: Pitter R, Kalin H, editors. The Calcitonins: Physiology and Pharmacology. Basel: Karger, 1989:134.
25. Gambacciani M, Melis GB, Spinetti A, Caffi T, Beretta A, Fioretti P. Evaluation of tolerability of the therapy with nasal calcitonin in postmenopausal women. XII World Congr Gynecology and Obstetrics, Rio de Janeiro, Brazil, October 23-28, Abstract Book, 1988:446.